The genotyping of UGT1A1 polymorphism for the dose adjustment of irinotecan in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab as the first-line regimen
Biomarkers and Genomic Medicine · 2013
DOI: 10.1016/j.bgm.2013.08.020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomarkers and Genomic Medicine, 2013. Verfasst von Chien-Yu Lu und 2 weiteren Autor:innen.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Lu, C., Tsai, H., & Wang, J. (2013). The genotyping of UGT1A1 polymorphism for the dose adjustment of irinotecan in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab as the first-line regimen. Biomarkers and Genomic Medicine. https://doi.org/10.1016/j.bgm.2013.08.020
Vancouver
Lu C, Tsai H, Wang J. The genotyping of UGT1A1 polymorphism for the dose adjustment of irinotecan in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab as the first-line regimen. Biomarkers and Genomic Medicine. 2013. doi:10.1016/j.bgm.2013.08.020
BibTeX
@article{Lu2013,
author = {Lu, Chien-Yu and Tsai, Hsiang-Lin and Wang, Jaw-Yuan},
title = {The genotyping of UGT1A1 polymorphism for the dose adjustment of irinotecan in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab as the first-line regimen},
journal = {Biomarkers and Genomic Medicine},
year = {2013},
doi = {10.1016/j.bgm.2013.08.020}
}
EUVIMED